Browse the evidence

Regular physical activity induces systemic molecular adaptations across multiple organ systems, reducing the risk of cardiovascular, metabolic, and mental health diseases through mechanisms involving energy mobilization, structural adaptation, and exerkine signaling.

Make movement a non-negotiable part of your daily routine, not an optional extra. Your body is biologically designed for activity, and regular exercise is one of the most powerful tools you have to prevent heart disease, metabolic issues, and mental health disorders. Focus on consistency across different types of movement (endurance, resistance) to trigger these protective molecular adaptations.

Obesity is a chronic disease of dysregulated energy balance involving neuroendocrine factors, requiring lifelong, multimodal management (lifestyle, pharmacotherapy, surgery) tailored to individual patient characteristics and evolving goals.

Treat obesity as a chronic disease requiring long-term management. Work with your healthcare provider to create a personalized plan involving lifestyle changes, medications, or surgery based on your specific health needs and goals. Regular follow-up is essential to adjust treatment as your needs change.

High-intensity interval exercise (HIIE) induces time-dependent transcriptomic changes in skeletal muscle that persist for at least 48 hours, with the magnitude of expression for 60% of genes being influenced by cardiorespiratory fitness.

To maximize molecular adaptations, ensure your exercise intensity is relative to your current fitness level (e.g., using lactate threshold or max work rate) rather than a fixed percentage. Recognize that the body's molecular response to exercise continues for up to 48 hours, with significant changes occurring well after the workout ends. This applies to both men and women when fitness levels are comparable.

A Fasting-Mimicking Diet (FMD) is a specific diet composed to induce the metabolic effects of fasting while allowing for a potentially higher caloric intake, typically up to 1,000 kcal/day, and is not classified as modified fasting.

A Fasting-Mimicking Diet (FMD) is a specific, formulated diet that mimics the metabolic effects of fasting. It allows up to 1,000 kcal per day for 3-7 days and is distinct from modified fasting, which is capped at 25% of energy needs.

Sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB) produce clinically equivalent long-term excess BMI loss, though RYGB yields significantly higher total weight loss and superior resolution of dyslipidemia.

If you are considering bariatric surgery, understand that both sleeve gastrectomy and Roux-en-Y gastric bypass provide similar long-term excess weight loss results. However, RYGB offers better improvement in cholesterol levels (dyslipidemia) and a lower risk of developing new acid reflux (GERD). Sleeve gastrectomy has a lower rate of minor complications. Your choice should be based on your existing health conditions, particularly whether you suffer from reflux, rather than the assumption that one surgery is strictly 'better' for weight loss.

For South and Southeast Asian populations, obesity diagnostic thresholds should be lowered (BMI ≥23 kg/m² for overweight, ≥25 kg/m² for obesity) because Asians exhibit higher visceral adiposity and cardiometabolic risk at lower BMIs compared to Caucasian populations.

If you are of South or Southeast Asian descent, do not rely solely on the standard BMI cutoff of 30 to define obesity. Your health risks for diabetes and heart disease increase at lower weights. Use the lower thresholds (Overweight ≥23, Obese ≥25) or waist circumference measurements to assess your risk, and consult a clinician for a full metabolic workup even if your BMI appears 'normal' by international standards.

Individuals with Type 2 Diabetes (T2D) exhibit significantly reduced cardiorespiratory fitness (CRF), measured as peak oxygen uptake (VO2peak), compared to healthy controls, with reductions averaging 13.9% for absolute VO2peak and 17.4% for relative VO2peak.

If you have Type 2 Diabetes, expect your maximum oxygen uptake to be lower than a healthy peer's, even if you feel fine. This is a physiological marker of the disease, not a lack of effort. Start exercise interventions at a lower intensity to manage early fatigue, and focus on consistency rather than high intensity initially, as improving this baseline fitness is critical for long-term health outcomes.

Higher BMI, particularly severe obesity (Class 2 and 3), is robustly associated with increased risk of heart failure and atrial fibrillation, independent of traditional risk factors.

Maintaining a healthy weight is critical for preventing heart failure and irregular heartbeats. Severe obesity significantly increases these risks, even if your blood pressure and cholesterol are managed. Weight management should be treated as a primary medical intervention to protect heart health.

Higher BMI categories, particularly Class III obesity (BMI ≥40 kg/m2), are strongly associated with worse self-reported overall health, quality of life, severe pain, fatigue, and limited physical activity, as well as an increased risk of developing chronic pain syndrome, chronic fatigue syndrome, fibromyalgia, and insomnia.

If you have obesity, do not ignore persistent pain, fatigue, or sleep issues. These are not just 'side effects' of weight but significant health risks linked to conditions like fibromyalgia and chronic fatigue. Seek medical evaluation for these symptoms, as treating them can improve your quality of life and functional ability, independent of weight loss goals.

Obesity is a chronic, relapsing disease driven by disruptions in homeostatic, hedonic, and cognitive systems, rather than solely a lifestyle outcome, and requires multidisciplinary management including pharmacotherapy and surgery.

Treat obesity as a chronic disease, not a lifestyle failure. For eligible patients, GLP-1 agonists like semaglutide (2.4 mg weekly) combined with lifestyle changes produce significant weight loss (approx. 15%). Manage GI side effects with slow titration. Consider surgery for BMI ≥35.

Obesity is a primary driver of Heart Failure with Preserved Ejection Fraction (HFpEF) through cardiometabolic mechanisms including systemic inflammation, lipotoxicity, and metabolic remodeling, rather than being merely a comorbidity.

If you have HFpEF and obesity, your body's metabolism and inflammation are likely driving your heart condition. This is not just about 'being overweight' but involves complex biological changes like fat toxicity and inflammation. Managing obesity through weight loss interventions (like GLP-1 agonists or lifestyle changes) can target these root causes and improve heart health.

Sarcopenic obesity is defined by the co-existence of excess adiposity and low skeletal muscle mass/function, requiring a two-step diagnostic algorithm of screening followed by functional and body composition assessment.

To identify sarcopenic obesity, first screen for high BMI or waist circumference. If positive, test muscle function (e.g., handgrip strength). If function is low, assess body composition (DXA or BIA) to confirm low muscle mass relative to fat. This two-step process ensures accurate diagnosis without unnecessary expensive testing for everyone.

Metabolic and bariatric surgery (MBS) is recommended for individuals with BMI >35 kg/m2 regardless of comorbidity status, and for those with BMI 30-34.9 kg/m2 who have metabolic disease or fail nonsurgical treatments.

If your BMI is over 35, surgery is a recommended first-line treatment option, not just a last resort. If your BMI is between 30 and 35, you should still consider surgery, especially if you have diabetes or other metabolic issues, or if lifestyle changes haven't worked. For Asian individuals, the thresholds are lower (BMI >27.5 for surgery consideration).

High body mass index (BMI > 25 kg/m²) is a major global health risk factor that has caused a more than 2.5-fold increase in global deaths and disability-adjusted life years (DALYs) between 1990 and 2021, with cardiovascular diseases and diabetes being the leading causes of this burden.

High body mass index (BMI) is a major, modifiable risk factor for serious diseases like heart disease, diabetes, and kidney disease. The global burden of disease from high BMI has more than doubled in 30 years. To protect your health, it is crucial to monitor your BMI and work towards maintaining a healthy weight through sustainable lifestyle changes, as high BMI significantly increases your risk of premature death and disability.

Fad diets, supplements, and unproven therapies (e.g., phytotherapics, probiotics for weight loss) are ineffective and potentially harmful for obesity treatment.

Avoid fad diets and unproven supplements (phytotherapics, probiotics, caffeine supplements) for weight loss. They are ineffective and may be harmful. Focus on evidence-based strategies like calorie restriction and behavioral changes.

Training status (years of experience) and sex do not significantly improve the predictive accuracy of dose-response models for resistance training outcomes.

You do not need to drastically change your core training variables (load, volume) based solely on your sex or years of training experience. Focus on matching load to your specific performance goal.

Obesity is a complex, chronic, multifactorial disease driven by genetic, epigenetic, psychosocial, and microenvironmental factors, rather than solely an energy imbalance.

Stop viewing obesity as a simple failure of willpower or calorie counting. Recognize it as a complex biological disease involving genetics, gut health, and stress. This shifts the focus from self-blame to seeking comprehensive medical and lifestyle interventions that address these underlying drivers.

Obesity is an independent proarrhythmic risk factor for both atrial and ventricular arrhythmias, mediated by structural remodeling (atrial/ventricular dilation, epicardial fat infiltration) and electrophysiological changes (prolonged QTc, P-wave dispersion).

Obesity directly increases the risk of heart rhythm problems (atrial and ventricular arrhythmias) through structural changes like heart enlargement and fat infiltration around the heart. This risk exists independently of other conditions like high blood pressure. Weight loss is a key intervention to reduce this risk.

Body Mass Index (BMI) is an inadequate and potentially misleading metric for assessing individual cardiometabolic risk because it fails to account for regional fat distribution and ectopic lipid deposition, which are the true drivers of disease.

Stop using BMI as your primary health metric. Instead, focus on waist circumference and metabolic markers (blood pressure, lipids, glucose). If you have a high BMI but a small waist and good metabolic markers, your risk may be low. Conversely, if you have a normal BMI but a large waist, your risk may be high. Prioritize lifestyle habits (diet quality, physical activity) that reduce visceral fat rather than just total weight.

Exposure to aerial environmental stressors, specifically fine particulate matter (PM2.5) and gaseous pollutants, causes cardiovascular disease and mortality through systemic inflammation, oxidative stress, and autonomic nervous system imbalance.

Monitor local air quality indices (AQI) and smog alerts. On days with high pollution, limit prolonged outdoor exertion, especially near traffic. Consider using air purifiers indoors and keeping windows closed during peak pollution times. This is a modifiable risk factor that acts independently of your diet and exercise habits.

Nutritional supplementation alone does not improve mobility or physical function in older adults when compared to physical activity interventions.

Do not rely on supplements to keep you mobile. While a healthy diet is important, it does not replace the need for physical activity. Focus on exercise groups rather than buying supplements for mobility.

Imaging-based body composition assessment (DXA, CT, or MRI) is required to demonstrate that weight loss from anti-obesity drugs is attributable to fat mass reduction rather than lean mass loss, as mandated by updated US FDA and Korean MFDS guidelines.

If you are taking anti-obesity medication, ask your provider about body composition analysis (DXA or CT) rather than relying solely on weight. This ensures your weight loss is coming from fat stores and not muscle tissue, which is critical for long-term metabolic health and is now a regulatory standard for drug approval.

DXA is the preferred imaging modality for anti-obesity drug trials due to its balance of low radiation, cost-effectiveness, and accessibility, although CT and MRI offer superior precision for visceral fat and muscle quality assessment.

For most obesity drug trials, DXA is the standard imaging tool because it is cheap, safe, and widely available. However, if detailed analysis of visceral fat or muscle quality (myosteatosis) is needed, CT or MRI may be used despite higher costs.

BMI is a valid and necessary tool for population-level surveillance of adiposity and obesity risk, but its use in individual clinical treatment decisions is inappropriate without additional measures.

Use BMI as a general screening tool for population health, not as a definitive diagnosis for individuals. If you are concerned about your health, ask for a comprehensive assessment including metabolic markers, not just a weight-based calculation.